Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD

Inflammatory Bowel Diseases

Volumn 21, Issue 6, 2015, Pages 1297-1305

  Lissner, Donata ^a   Schumann, Michael ^a   Batra, Arvind ^a   Kredel, Lea Isabel ^a   Kühl, Anja A ^a   Erben, Ulrike ^a   May, Claudia ^a   Schulzke, Jörg Dieter ^a   Siegmund, Britta ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Crohn's disease; epithelial barrier; Inflammatory bowel diseases; macrophage subtypes

Indexed keywords

CLAUDIN 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; CD14 ANTIGEN; CD68 ANTIGEN, HUMAN; CYTOKINE; DIFFERENTIATION ANTIGEN; INFLAMMASOME; LEUKOCYTE ANTIGEN; NITRIC OXIDE SYNTHASE;

ADULT; APOPTOSIS; ARTICLE; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; LAMINA PROPRIA; MACROPHAGE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADOLESCENT; AGED; CYTOLOGY; EPITHELIUM CELL; INFLAMMATORY BOWEL DISEASES; INTESTINE; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; CLAUDIN-2; CYTOKINES; EPITHELIAL CELLS; HUMANS; INFLAMMASOMES; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; MACROPHAGES; MIDDLE AGED; MONOCYTES; NITRIC OXIDE SYNTHASE; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; YOUNG ADULT;

EID: 84929849408     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000384     Document Type: Article

References (36)

1. McGovern DP, van Heel DA, Ahmad T, et al. NOD2 (CARD15), the first susceptibility gene for Crohn's disease. Gut. 2001;49:752-754.
2. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med. 2005;352:2193-2201.
3. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002;360:1478-1480.
4. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-452.
5. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol. 1997;159:6276-6282.
6. Schmitz H, Fromm M, Bentzel CJ, et al. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci. 1999;112(pt 1):137-146.
7. McGuckin MA, Eri R, Simms LA, et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009;15:100-113.
8. Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut. 2004;53:1295-1302.
9. Satsu H, Ishimoto Y, Nakano T, et al. Induction by activated macrophagelike THP-1 cells of apoptotic and necrotic cell death in intestinal epithelial Caco-2 monolayers via tumor necrosis factor-alpha. Exp Cell Res. 2006; 312:3909-3919.
10. Scholmerich J, Huber G. Biological therapy in IBD. Anti-tumor necrosis factor-alpha and others. Dig Dis. 2003;21:180-191.
11. Lugering A, Lebiedz P, Koch S, et al. Apoptosis as a therapeutic tool in IBD? Ann N Y Acad Sci. 2006;1072:62-77.
12. Vos AC, Wildenberg ME, Arijs I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis. 2012;18:401-408.
13. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177: 7303-7311.
14. Takada Y, Hisamatsu T, Kamada N, et al. Monocyte chemoattractant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-producing regulatory macrophage subset. J Immunol. 2010;184:2671-2676.
15. Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest. 2005;115:66-75.
16. Kreusel KM, Fromm M, Schulzke JD, et al. Cl-secretion in epithelial monolayers of mucus-forming human colon cells (HT-29/B6). Am J Physiol. 1991;261(4 pt 1):C574-C582.
17. Schumann M, Richter JF, Wedell I, et al. Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut. 2008;57: 747-754.
18. Edens HA, Levi BP, Jaye DL, et al. Neutrophil transepithelial migration: evidence for sequential, contact-dependent signaling events and enhanced paracellular permeability independent of transjunctional migration. J Immunol. 2002;169:476-486.
19. Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease. Gut. 2013;62:852-862.
20. Schumann M, Gunzel D, Buergel N, et al. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut. 2012;61:220-228.
21. Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. J Innate Immun. 2011;3:550-564.
22. Schulzke JD, Ploeger S, Amasheh M, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 2009;1165:294-300.
23. Amasheh S, Meiri N, Gitter AH, et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci. 2002;115(pt 24):4969-4976.
24. Fujita H, Chiba H, Yokozaki H, et al. Differential expression and subcellular localization of claudin-7,-8,-12,-13, and-15 along the mouse intestine. J Histochem Cytochem. 2006;54:933-944.
25. Al-Sadi RM, Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol. 2007;178:4641-4649.
26. Lissner D, Siegmund B. The multifaceted role of the inflammasome in inflammatory bowel diseases. ScientificWorldJournal. 2011;11: 1536-1547.
27. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut. 1989;30:835-838.
28. Netea MG, Nold-Petry CA, Nold MF, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 2009;113:2324-2335.
29. Pull SL, Doherty JM, Mills JC, et al. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA. 2005; 102:99-104.
30. Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc regiondependent manner. Gastroenterology. 2011;140:221-230.
31. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
32. Caprioli F, Bose F, Rossi RL, et al. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy. Inflamm Bowel Dis. 2013;19:729-739.
33. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
34. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003;73:209-212.
35. Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and antiinflammatory macrophage function. Immunity. 2014;40:706-719.
36. Zigmond E, Bernshtein B, Friedlander G, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity. 2014;40:720-733.